Section
A comprehensive UK cohort study shows that GLP-1 receptor agonists do not reduce the incidence of obstructive sleep apnea compared to DPP-4 inhibitors in obese patients with type 2 diabetes.
This article reviews exploratory analyses from a phase 2b trial examining eosinophil count changes in adults with uncontrolled moderate-to-severe asthma treated with the IL-4Rα inhibitor rademikibart, indicating a low risk of treatment-emer
Distinct Pseudomonas aeruginosa abundance and interaction patterns in bronchiectasis patients reveal heterogeneity influencing clinical outcomes and treatment responses, offering new avenues for personalized management.
Comprehensive exome sequencing reveals genetic heterogeneity in persistent tachypnea of infancy (PTI/NEHI), highlighting its phenotype nature and association with neurodevelopmental disorders, advocating early genetic testing to enhance dia
Mechanical ventilation during surgery induces neutrophil extracellular vesicles that propagate lung inflammation and contribute to postoperative pulmonary complications, highlighting potential new biomarkers and therapeutic targets.
Host blood transcriptomic signatures effectively monitor treatment response and predict recurrence and mortality in drug-susceptible pulmonary tuberculosis, meeting WHO benchmarks and enabling personalized therapy strategies.
Earlier initiation of biologic therapies in severe asthma improves clinical remission rates, reduces exacerbations, preserves lung function, and decreases corticosteroid dependence, supporting a shift from reserving to preserving treatment
This study evaluates ECMO as a standalone respiratory support in ARDS patients avoiding invasive mechanical ventilation, highlighting outcomes, strategy failures, and mortality implications.
This review summarizes the progression risk from mild-to-moderate to severe asthma based on the NORDSTAR cohort and integrates emerging evidence on biologic therapies that improve severe asthma outcomes across diverse patient profiles.
This study reveals unique fatty acid and oxylipin metabolic signatures that differentiate isolated postcapillary pulmonary hypertension from combined pre- and postcapillary PH, highlighting potential biomarkers and therapeutic targets.
Rapid immunoassay-based classifiers accurately identify hyper- and hypoinflammatory subphenotypes in critically ill children, preserving prognostic and predictive utility and enabling precision therapies in acute pediatric cardiorespiratory
Astegolimab, an anti-ST2 monoclonal antibody, significantly reduced moderate/severe exacerbations in COPD patients with frequent exacerbations in pooled ALIENTO and ARNASA analyses, showing promise for targeting the IL-33/ST2 pathway with g
The PASSAGE phase 4 study reveals tezepelumab significantly reduces exacerbation rates and improves lung function and quality of life in a broad US severe asthma population, including underrepresented groups and varied phenotypes.
Dupilumab significantly reduces emergency visits, hospital admissions, and systemic corticosteroid use in COPD patients with type 2 inflammation, offering a promising therapeutic option to mitigate exacerbation-associated morbidity.
This study explores the high prevalence of voice fatigue among e-cigarette users and its significant correlation with dry mouth (xerostomia).
This review synthesizes emerging evidence demonstrating robust effectiveness of RSV vaccination in reducing hospitalization, death, and severe outcomes among elderly nursing home residents during the vaccine’s inaugural season.
This study demonstrates that combining quantitative CT biomarkers with clinical data significantly improves the detection of previously undiagnosed COPD within lung cancer screening populations, optimizing referrals for confirmatory spirome
A newly developed clinical likelihood score accurately distinguishes pulmonary arterial hypertension patients with venous or capillary involvement (PVOD/PCH), enabling earlier diagnosis, tailored therapy, and timely transplant referral.
Expiratory pressure alleviation during CPAP treatment reduces upper airway patency, increases residual apnea severity, and necessitates higher therapeutic pressure in severe OSA patients, without affecting treatment adherence.
This study evaluates days alive and out of hospital (DAOH) around lung transplantation, identifying predictors of reduced DAOH in the first post-transplant year and providing insights for tailored patient counseling and care strategies.
